Karius Overview

  • Founded
  • 2014

Founded
  • Status
  • Private

  • Employees
  • 165

Employees
  • Latest Deal Type
  • Series B

  • Investors
  • 14

Karius General Information

Description

Operator of a clinical laboratory testing center intended to focus on generating genomic insights for infectious diseases. The company's tests map each patient's microbial landscape from a single blood draw and develop molecular biology and data analysis tools that use deep sequencing to detect minuscule traces of microbial deoxyribonucleic acid (DNA) directly from blood, enabling physicians to make rapid life-saving treatment decisions in a hassle-free manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Primary Office
  • 975 Island Drive
  • Suite 101
  • Redwood City, CA 94065
  • United States
+1 (866) 000-0000

Karius Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Karius Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 07-Mar-2022 00000 Completed Generating Revenue
6. Later Stage VC (Series B) 20-Jan-2021 000 00000 Completed Generating Revenue
5. Later Stage VC (Series B) 20-Jan-2020 00000 00000 Completed Generating Revenue
4. Debt - General 30-Nov-2018 0000 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 07-Aug-2017 0000 000.00 00000 Completed Generating Revenue
2. Accelerator/Incubator $5.27M Completed Startup
1. Seed Round 20-Oct-2014 $5.27M $5.27M 000.00 Completed Startup
To view Karius’s complete valuation and funding history, request access »

Karius Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Karius’s complete cap table history, request access »

Karius Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical laboratory testing center intended to focus on generating genomic insights for infectious disease
Biotechnology
Redwood City, CA
165 As of 2022
00000
00000000000 00000

000000

nt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco labo
0000000000000
Saint Louis, MO
00 As of 0000
000.00
000000000 - 000.00

000000

ng elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000000000 00000000 (0000000000)
San Diego, CA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Karius Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adarza BioSystems Venture Capital-Backed Saint Louis, MO 00 000.00 000000000 - 000.00
0000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
00000000 0000000 0 Formerly VC-backed Castel Maggiore, Italy 00000 000.00 000000&0 000.00
00000000 000000000 Formerly VC-backed Seattle, WA 000 00000 00000000 00000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
You’re viewing 5 of 9 competitors. Get the full list »

Karius Patents

Karius Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3884087-A1 Detection and prediction of infectious disease Pending 21-Nov-2018 0000000000
CA-3118742-A1 Detection and prediction of infectious disease Pending 21-Nov-2018 0000000000
EP-3884065-A1 Direct-to-library methods, systems, and compositions Pending 21-Nov-2018 0000000000
CA-3118990-A1 Direct-to-library methods, systems, and compositions Pending 21-Nov-2018 0000000000
EP-3765592-A1 Sample series to differentiate target nucleic acids from contaminant nucleic acids Pending 16-Mar-2018 C12Q1/6806
To view Karius’s complete patent history, request access »

Karius Executive Team (12)

Name Title Board Seat Contact Info
Alec Ford Chief Executive Officer
William Quirk Chief Financial Officer
Sivan Bercovici Ph.D Chief Technology Officer
Steve Malaska Chief Legal Officer
Tim Blauwkamp Ph.D Co-Founder, Chief Scientific Officer & Board Member
You’re viewing 5 of 12 executive team members. Get the full list »

Karius Board Members (5)

Name Representing Role Since
Tim Blauwkamp Ph.D Karius Co-Founder, Chief Scientific Officer & Board Member 000 0000
You’re viewing 1 of 5 board members. Get the full list »

Karius Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Karius Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
General Catalyst Venture Capital Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
SoftBank Investment Advisers Growth/Expansion Minority 000 0000 000000 0
Casdin Capital Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »